LINDIS Biotech Partners with Pharmanovia for Catumaxomab Launch

Lindis Biotech GmbH has announced a licensing agreement with Pharmanovia to commercialize Catumaxomab, a bifunctional antibody therapy. This partnership follows a positive review from the EMA's Committee for Medicinal Products for Human Use in October 2024. Subject to approval, Catumaxomab will be the first drug sanctioned for malignant ascites treatment, a condition commonly linked to advanced cancers like ovarian and pancreatic. Pharmanovia will spearhead marketing efforts.

This collaboration highlights Catumaxomab's potential in cancer therapy. The drug targets EpCAM-positive carcinomas, aiming to improve patient quality of life by reducing puncture dependence and possibly extending lifespan. Previous research indicates its efficacy in over 2000 patients prior to its market withdrawal in 2014. Wiederaufnahme was conducted due to commercial strategies.

Executives from both companies expressed optimism about easing the burden of malignant ascites on patients, stressing the importance of bringing Catumaxomab back to the market.